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Abstract
Overproduction of type I collagen is associated with a wide
range of fibrotic diseases as well as surgical failure such as
in glaucoma filtration surgery (GFS). Its modulation is
therefore of clinical importance. Valproic acid (VPA) is
known to reduce collagen in a variety of tissues with un-
clear mechanism of action. In this report, we demonstrate
that VPA inhibited collagen production in both conjunctival
fibroblasts and the mouse model of GFS. In fibroblasts,
VPA decreased type I collagen expression which intensified
with longer drug exposure and suppressed steady-state type
I collagen promoter activity. Moreover, VPA decreased
Smad2, Smad3 and Smad4 but increased Smad6 expression
with a similar intensity-exposure profile. Reduction of
Smad3 using small hairpin RNA and/or overexpression of
Smad6 resulted in decreased collagen expression which
was exacerbated when VPA was simultaneously present.
Furthermore, fibrogenic TGF-β2 failed to induce collagen
when VPA was present, as opposed to the myofibroblast
markers, beta-actin, alpha-smooth muscle actin and
tenascin-C, which were elevated by TGF-β2. VPA sup-
pressed p3TP-Lux luciferase activity and selectively res-
cued Smad6 expression from suppression by TGF-β2. No-
tably, SMAD6 overexpression reduced the effectiveness of
TGF-β2 in inducing collagen expression. In corroboration,
VPA inhibited type I collagen but increased Smad6 expres-
sion in the late phase of wound healing in the mouse mod-
el of GFS. Taken together, our data indicate that VPA has
the capacity to effectively suppress both steady-state and
fibrogenic activation of type I collagen expression by mod-
ulating Smad expression. Hence, VPA is potentially appli-
cable as an anti-fibrotic therapeutic by targeting collagen.
Key message
• VPAmodulates type I collagen expression via members of
the Smad family.
• VPA suppresses Smad2, Smad3 and Smad4 but
upregulates Smad6.
• Smad3 and Smad6 are involved in VPA regulation of
steady-state collagen expression.
• Smad6 is involved in VPA modulation of TGF-β-
stimulated collagen expression.
• VPA reduces collagen and upregulates Smad6 in the
mouse model of glaucoma filtration surgery.
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Introduction
Type I collagen is the major component of extracellular matrix
of nearly every human organ and constitutes the most abun-
dant form of collagen in the human body. The main physio-
logical role of collagen is to provide an architectural scaffold
to strengthen and support tissues. In response to injury or
certain diseases, collagen production facilitates the restoration
of tissue homeostasis and normal physiological functions [1].
At times, however, this tissue repair response may be exag-
gerated, resulting in fibrosis or scarring. Indeed, the excessive
and abnormal accumulation of type I collagen is the hallmark
of fibrosis, and evident in many fibroproliferative medical
conditions where it may be life threatening whenmajor organs
such as the heart, lung and kidney are affected. Moreover,
accumulation of type I collagen is prevalent in many tumours
and associated with increased risk of metastasis and poor
prognosis [2]. In some surgeries such as glaucoma filtration
surgery (GFS), scarring is implicated to be the main cause of
surgical failure [3]. Hence, the modulation of type I collagen
production in these pathological contexts is of utmost biolog-
ical and clinical importance.
TGF-β stimulation of collagen synthesis plays a key role in
both physiological tissue repair and pathological fibrosis [1].
The core intracellular effectors of TGF-β signaling are Smads
[4]. Interestingly, Smads are also known to regulate steady-
state collagen expression [5]. Receptor-regulated Smads (R-
Smads: Smad1, Smad2, Smad3, Smad5 and Smad8) are the
downstream effectors of serine-threonine kinase receptors ac-
tivated by binding to the TGF-β superfamily of ligands [6].
Generally, stimulation by fibrogenic TGF-β leads to phos-
phorylation of Smad2 and Smad3 while other ligands like
the bone morphogenetic protein (BMP) induce phosphoryla-
tion of Smad1, Smad5 and Smad8. The common mediator
Smad4 (Co-Smad) is not ligand-restricted and form
heteromeric complexes with the activated R-Smads to accu-
mulate in the nucleus where they are directly involved in the
regulation of target gene transcription. On the other hand,
inhibitory Smads (I-Smads: Smad6 and Smad7) act in oppo-
sition to the R-Smads to negatively regulate TGF-β signaling
in a feedback loop.
Valproic acid (VPA) belongs to the short-chain fatty acid
class of histone deacetylase (HDAC) inhibitors. VPA has been
used for over two decades in the treatment of neurological
disorders [7] and is currently under clinical investigation as
an anticancer drug with promising outcomes [8]. Although
HDAC has been suggested to be a potential target for fibrotic
disorders [9], the effect of VPA on wound healing and fibrosis
is obscure. VPA has been shown to reduce muscle collagen
content [10] and renal fibrosis [11], inhibit collagen deposition
and activation of hepatic stellate cells [12] as well as reduce
cutaneous radiation syndrome in rats [13]. In apparent contra-
diction, VPA was reported to accelerate cutaneous wound
healing, in part by increasing collagen production [14]. The
molecular mechanism for VPA effects on wound healing is
even less well understood. In renal tubular epithelial cells,
VPA has been shown to reduce the mRNA expression of
colony-stimulating factor-1 [15] or suppress epithelial-to-
mesenchymal transition [16]. On the other hand, the reduction
in the radiation-induced wound response due to VPA correlat-
ed with the suppression of aberrant TGF-β and tumour necro-
sis factor-α expression [13]. Clearly, the therapeutic potential
of VPA to reduce collagen production and the associated
mechanisms need further validation.
In this study, we investigated the effect and mechanism of
VPA activity on type I collagen production in conjunctival
fibrosis. Conjunctival fibroblasts have been implicated as the
main effector cells that elicit the fibrotic response in GFS
[17–19]. Our data revealed that VPA has the capacity to re-
duce type I collagen expression in conjunctival fibroblasts at
the steady-state as well as in the presence of TGF-β2. More-
over, we determined that while the effect of VPA on basal
collagen may involve several members of the Smad family,
particularly Smad3 and Smad6, the inhibitory effect of VPA in
the fibrogenic activation of collagen by TGF-β2 selectively
involved Smad6. The in vitro findings were corroborated in
the mouse model of GFS [20] where type I collagen and
Smad6 were modulated by VPA in a similar manner. Taken
together, our study indicates that VPA is an effective inhibitor
of collagen production via the disruption of both steady-state
and TGF-β regulatory pathways mediated in part by Smads.
Materials and methods
Primary conjunctival fibroblast cell culture, treatments
and transfections
Primary conjunctival fibroblasts were obtained from the eyes
of C57BL6/J mice and cultured as described previously [21].
Treatment with valproic acid (Sigma-Aldrich Co., St. Louis,
MO), was carried out at 300 μg/ml (or 2 mM) for 72 h unless
otherwise indicated. Treatment with TGF-β2 (PeproTech Inc.,
NJ, USA) was performed at 8 ng/ml. Transfections were per-
formed using the P2 primary cell 4D Nucleofector kit L
(Lonza, Basel, Switzerland) and the 4D-Nucleofactor X unit
(Lonza) according to manufacturer’s protocol. The shRNA for
mouse Smad3 (referred to as shSmad3 in the text) was a gift
from Vicki Boussiotis (Addgene plasmid # 32806) while the
negative control for this plasmid was the piGENETMU6 Rep
vector purchased from iGene Therapeutics, Inc (Tsukuba, Ja-
pan). The expression vector for mouse Smad6 (referred to as
pSmad6 in the text) was purchased from GE Healthcare
Dharmacon Inc. (CO, USA) while the negative control for this
plasmid was pcDNA3.1(-) (Invitrogen Corp., Carlsbad,
USA). For single transfection, 1 μg of plasmid was used per
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1×105 cells. For co-transfection with both shSmad3 and
pSmad6 in the experimental arm or their respective vectors
in the control arm, 800 ng of each plasmid was used per 1×
105 cells. Fibroblasts were cultured for 72 h after transfection
before analyses, unless otherwise indicated. For co-treatment
with VPA and/or TGF-β2, the transfected cells were allowed
to recover for 24 h post-transfection before incubation with
the indicated treatments for 72 h.
Mouse model of GFS
All experiments with animals were approved by the Institu-
tional Animal Care and Use Committee (IACUC) and treated
in accordance with the Association for Research in Vision and
Ophthalmology (ARVO) Statement on the Use of Animals in
Ophthalmic and Vision Research. NIH3T3/BL6 mice were
obtained from the National University of Singapore Centre
for Animal Resources. Experimental surgery was performed
as described previously [21] on one eye while the contralateral
unoperated eye was used as baseline for comparison. VPAwas
injected at 300 μg/ml (5 μl) into the conjunctiva of the oper-
ated eye immediately after and on day 2 post-surgery if the
tissues were harvested on day 7 post-surgery. PBS was used as
control and given at the same regimen.
Real-time quantitative PCR analysis
Conjunctival fibroblasts and conjunctival tissues were proc-
essed and analysed as described previously [22, 23]. All PCR
reactions were performed in triplicate in each set of experi-
ment and three sets of independent experiments were per-
formed for every interrogation, unless otherwise indicated.
All mRNA levels were measured as CT threshold levels. The
best housekeeping gene for each experimental condition was
determined using the NormFinder software [24]. Values were
calculated as fold change by the 2−ΔΔCT method. Data is pre-
sented as the mean of the fold changes derived from each of
the three sets of independent experiments comparing the rele-
vant conditions, unless otherwise indicated. Primers for 18S
rRNAwere described previously [23]. Other primer sequences
were as follows: Acta2-forward, 5′-CTGCCGAGCGTG
AGATTG-3′ and Acta2-reverse, 5′-ATAGGTGGTTTCGTG
GATGC-3′; Actb-forward, 5′-CACCCGCGAGCACAGCT
TCT-3′, and Actb-reverse, 5′-CGTTGTCGACGACCAGCG
CA-3′; Gapdh-forward, 5′- GCCAAGGCTGTGGGCAAGG
T-3′, and Gapdh-reverse, 5′-TCTCCAGGCGGCACGTCAG
A-3′; Rpl13a-forward, 5′-GAGGTCGGGTGGAAGTACCA-
3′, and Rpl13a-reverse, 5′-TGCATCTTGGCCTTTTCCTT-
3′; Col1a1-forward, 5′-CCCACCCCAGCCGCAAAGAG-3′,
and Col1a1-reverse, 5′- GCCATGCGTCAGGAGGGCAG-
3′; Smad2-forward, 5′- ATGTCGTCCATCTTGCCATTC-3′,
and Smad2-reverse, 5′-AACCGTCCTGTTTTCTTTAGCTT-
3′; Smad3-forward, 5′- CATTACCATCCCCAGGTCAC-3′,
and Smad3-reverse, 5′-CGTAATTCATGGTGGCTGTG-3′;
Smad4-forward, 5′-GTTCAGGTAGGAGAGACGTTTAA
GGT -3′, and Smad4-reverse, 5′- CCTTTACATTCCAACT
GCACTCCT-3′; Smad6-forward, 5′-TACCACTTCAGCCG
GCTCTG-3′, and Smad6-reverse, 5′-AGTACGCCACGC
TGCACCAGT-3′; Smad7-forward, 5′- GACTCCAGGACG
CTGTTGGT-3′, and Smad7-reverse, 5′-CCATGGTTGCTG
CATGAACT-3′; Tnc-forward, 5′-ACCATGCTGAGATA
GATGTTCCAAA-3′, and Tnc-reverse, 5′-CTTGACA
GCAGAAACACCAATCC-3′.
Real-time cell proliferation analysis
The xCelligence real-time cell analyser (Roche Diagnostics
GmbH, Penzberg, Germany) was used to assess cell prolifer-
ation according to manufacturer’s instructions. Fibroblasts
were seeded onto the E-Plate 96 (Roche Diagnostics GmbH)
wells at 2000 cells/well in normal culture medium, in quadru-
plicates. Adherent cell growth/density was monitored contin-
uously for up to 5 days.
Annexin V and viability assays by flow cytometry
Apoptosis was measured using the Guava Nexin Reagent
(Guava Technologies, Hayward, CA, USA) while cell viabil-
ity was measured using the Guava ViaCount assay (Guava
Technologies) by flow cytometry. Primary mouse conjuncti-
val fibroblasts were trypsinized at 72 h post-VPA treatment
and processed according to manufacturer’s instructions. Each
condition was performed in triplicates. Five thousand cells
were analysed for each sample. Cell populations were quanti-
fied using the Guava EasyCyte Plus flow cytometry system
(Guava Technologies).
Immunoblotting
Whole cell lysates and tissue lysates were resolved by SDS-
polyacrylamide gel electrophoresis followed by immunoblot-
ting as previously described [22, 23]. Anti-type I collagen was
from MD Bioproducts (St Paul, MN). Antibodies against
SMAD2/3 and SMAD6were fromCell Signaling Technology
(Danvers, MA) and Abcam Plc (Cambridge, UK), respective-
ly. The Smad2 (pSer465/467) antibody was obtained from
Calbiochem (EMDMillipore, San Diego, CA). Both antibod-
ies against SMAD4 and GAPDH were from Santa Cruz Bio-
technology, Inc. (Santa Cruz, CA). Horseradish peroxidase
(HRP)-conjugated secondary antibodies were from Jackson
Immunoresearch Laboratories, Inc. (West Grove, PA). Densi-
tometric analyses, where potential errors in loading were
corrected to levels of the housekeeping GAPDH, were per-
formed as reported previously [22]. Three sets of independent
experiments were performed for every interrogation, unless
otherwise indicated. Densitometric data is presented as the
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mean of the fold changes derived from each of the three sets of
independent experiments comparing the relevant conditions,
unless otherwise indicated.
Immunofluorescence and picrosirius red polarisation
microscopy
Cryosections of day 7 post-operated eye tissues and
picrosirius red staining were performed as described previous-
ly [21]. Type I collagen antibody was obtained from MD
Bioproducts (St. Paul, MN). Labeling by the primary antibod-
ies was detected using secondary antibodies conjugated to
Alexa Fluor-594 (Invitrogen, Eugene, OR). Nuclei were
visualised by mounting the cells in DAPI-containing
Vectashield mounting medium (Vector Laboratories, CA,
USA). Labeled cells were visualised using the Zeiss
Imager.Z1 microscope (Carl Zeiss Inc., USA) while
polarisation microscopy was performed using the Nikon
Eclipse Ti microscope (Nikon Instruments Inc., NY, USA).
Reporter gene assays
The mouse ColI 3-0 Basic reporter construct includes 3200 nt
of mouse collagenα1(I) promoter cloned into the pGL3-Basic
vector [25]. The p3TP-lux reporter plasmid, a chimeric
TGF-β-inducible reporter comprising of three multimerized
TGF-β-binding elements, was a kind gift from Dr. Joan
Massague (Memorial Sloan-Kettering Cancer Center, New
York). 0.5 μg of reporter or control constructs were co-
transfected into 1×105 fibroblasts with 0.5 μg of the internal
control pRL-TK (Promega) using the P2 primary cell 4D
Nucleofector kit L (Lonza, Basel, Switzerland) and the 4D-
Nucleofactor X unit (Lonza) according to manufacturer’s pro-
tocol. The transfected cells were then treated with VPA and/or
TGF-β2 for 24 h the following day. Luciferase activity was
measured via the Tecan Infinite M200 reader (Tecan Trading
AG, Switzerland) using the Dual-Glo® Luciferase Assay sys-
tem (Promega) according to the manufacturer’s protocol and
values were normalised to Renilla luciferase activity. Each set
of experiment was performed in triplicate and three sets of
independent experiments were performed for each reporter
assay. Data is presented as the mean of the fold changes de-
rived from each of the three sets of independent experiments
comparing the relevant conditions, unless otherwise indicated.
Statistical analysis
Data are expressed as mean±standard deviation (SD). Where
only two treatment conditions were compared, the signifi-
cance of differences between the two conditions was deter-
mined by the two-tailed Student’s t test using the Microsoft
Excel 5.0 software, with significance at p<0.05. Where more
than two treatment conditions were compared, the
significance of differences between the conditions was deter-
mined by one-way ANOVA using SPSS statistics. Bonferroni
post hoc adjustment was applied to determine which condi-
tions were significantly different from each other.
Results
VPA inhibits steady-state type I collagen expression
in primary conjunctival fibroblasts
To determine the optimum dose of VPA for inhibition of type
I collagen expression, we performed a titration study of VPA
on primary cultures of conjunctival fibroblasts. VPA at a
concentration of 300 μg/ml (or 2 mM) was able to signifi-
cantly reduce Col1a1 mRNA expression (Fig. 1a) while
causing growth retardation with an average 6 % loss in cell
density compared to untreated cells over a growth period of
5 days (Fig. 1b). We further ascertained that VPA treatment
for 72 h resulted in 4.4 % more early apoptotic cells (Fig. 1c)
and 9.5 % less viable cells (Fig. 1d) compared to untreated
cells cultured for the same length of time. Hence, VPA treat-
ment of primary conjunctival fibroblasts at 300 μg/ml for
72 h is associated with lower cellular viability and higher
apoptosis rate.
We further verified that VPA inhibited type I collagen ex-
pression at the protein level (Fig. 1e). Notably, extended ex-
posure to VPA for 3 days compared to 1 day resulted in sig-
nificantly greater suppression of type I collagen expression.
To demonstrate that VPA regulates Col1a1 at the transcrip-
tional level, conjunctival fibroblasts were transfected with a
reporter plasmid driven by the Col1a1 promoter followed by
treatment with 300 μg/ml VPA. We observed that VPA sig-
nificantly reduced steady-state Col1a1 promoter activity
(Fig. 1f), confirming that VPA has the capacity to suppress
basal Col1a1 expression.
Since treatment with VPA at 300 μg/ml for 72 h was de-
termined to be effective in significantly suppressing Col1a1
expression with no greater than 10 % loss in cell viability,
subsequent investigation of VPA effects were measured under
these conditions, unless otherwise specified.
VPA suppresses steady-state Smad2, Smad3 and Smad4
but induces Smad6 expression
Since Smads are implicated in the regulation of collagen
expression, we examined the effect of VPA on Smads that
are involved in the fibrogenic pathway. The influence of VPA
on Smad transcript expression increased with increasing ex-
posure time (Fig. 2a). VPA treatment for 72 h caused a sig-
nificant downregulation of Smad2, Smad3 and Smad4
mRNAs by 19, 24 and 14 %, respectively, while Smad6
transcripts were upregulated by 22 % (Fig. 2a). VPA had
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no significant effect on Smad7 mRNA expression. The ratio
of the mRNA levels of positive Smad2 and negative Smad6
mediators of SMAD signaling (Smad2 mRNA: Smad6
mRNA ratio) was decreased upon VPA treatment, and the
difference was statistically significant between 48 and 72 h
(Fig. 2b). A similar phenomenon was observed for the ratio
of Smad3 and Smad6 mRNA levels (Fig. 2c). Hence, an
exposure time of 72 h to VPA was sufficient to produce
significant changes in Smad expression.
At the protein level, VPA also significantly inhibited
SMAD2 and SMAD3 expression (Fig. 2d). Extended expo-
sure to VPA for 3 days compared to 1 day also resulted in
significantly greater suppression of SMAD2 and SMAD3 ex-
pression in a profile similar to that of type I collagen. Between
the two, SMAD3 was reduced to a greater extent than
SMAD2 at both time points. SMAD4 protein expression
was also reduced with VPA treatment after 3 days (Fig. 2e).
The profile of SMAD6 was the opposite, with significantly
Fig. 1 VPA inhibits steady-state type I collagen expression. a Real-time
PCR analysis of Col1a1 expression in primary conjunctival fibroblasts
treated with increasing concentration of VPA for 72 h. Data are presented
as mean fold change±SD relative to untreated cells and are representative
of three independent sets of experiments. *p value comparing fold mRNA
between treatment with 300 μg/ml VPA and untreated controls is shown.
b Real-time cell proliferation analysis of fibroblasts treated with
300 μg/ml VPA. Data are presented as mean cell index±SD of
triplicates. c Early apoptosis of conjunctival fibroblasts treated with
VPA for 72 h. Left and middle panels, scatter plots of representative
control and VPA-treated samples with gatings and mean percentages of
early apoptotic cells indicated; right panel, data are presented as % early
apoptotic cells±SD of triplicates. *p value and the fold increase in early
apoptotic cells in VPA-treated cells compared to controls are shown. d
Viability of conjunctival fibroblasts treated with VPA for 72 h. Data are
presented as % viable cells±SD of triplicates. *p value and the fold
change in cell viability in VPA-treated cells compared to controls are
shown. e Immunoblot analysis of type I collagen in fibroblasts treated
with VPA for the indicated times. Representative immunoblots from one
experiment are shown. Densitometry values, normalised to GAPDH,
represent the means±SD of the folds expression of type I collagen in
VPA-treated relative to untreated cells. p values comparing VPA
treatment to control for each time point are *p=0.00145 and **p=
0.0000315. p value comparing fold changes between day 1 and day 3
is ***p=0.00173. C, control untreated cells. f Basal Col1a1 promoter
activity analysis. Fibroblasts were transfected with the Coll 3-0-Basic
reporter plasmid and treated with VPA for 24 h before firefly luciferase
activity wasmeasured. Data were normalised to Renilla luciferase activity
from co-transfected pRL-TK and presented as mean fold luciferase
activity±SD of VPA-treated relative to untreated cells
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more SMAD6 being expressed after 3 days of VPA treatment
(Fig. 2f). These data suggests a positive correlation between
type I collagen expression with that of SMAD2, SMAD3 and
SMAD4 and an inverse correlation with SMAD6.
Smad3 and Smad6 contribute to steady-state type I
collagen expression
To determine in greater detail the involvement of Smad3 and
Smad6 on VPA regulation of steady-state type I collagen ex-
pression, we used silencing and overexpression vectors of
Smads to mimic the effects of VPA. Since VPA suppressed
Smad3 expression, we simulated this effect in fibroblasts by
transfecting them with small hairpin RNA of Smad3
(shSmad3). This method resulted in the significant reduction
of Smad3 mRNA which was associated with a reduction in
Col1a1mRNA, supporting the involvement of Smad3 in reg-
ulating steady-state Col1a1 expression (Fig. 3a). Smad6 ex-
pression was not significantly affected by Smad3 downregu-
lation (data not shown).
Conversely, since VPA induced Smad6 expression, we
mimicked this effect in fibroblasts by transfecting them with
Fig. 2 VPA exerts differential regulation on Smad family members. a
Real-time PCR analyses of Smads in primary conjunctival fibroblasts
treated with VPA for 24, 48 and 72 h. Data are presented as mean fold
change±SD relative to untreated control. *p values comparing fold
mRNA between treatment with 300 μg/ml VPA for 72 h and untreated
controls are shown. b Ratio of Smad2:Smad6 mRNA levels at 24,
48 and 72 h. The fold change and p value between 48 and 72 h are
indicated. c Ratio of Smad3:Smad6 mRNA levels at 24, 48 and 72 h.
The fold change and p value between 48 and 72 h are indicated.
Immunoblot analyses of d SMAD2 and SMAD3, e SMAD4 and f
SMAD6 in fibroblasts exposed to VPA for the indicated times.
Representative immunoblots from one experiment of each SMAD are
shown. C, untreated controls. Densitometry values, normalised to
GAPDH, represent the means±SD of the folds expression in
VPA-treated relative to untreated cells of three (e, f), or four (d)
independent sets of experiments. Fold changes and the associated
p values, where significant, comparing the indicated conditions are
shown. d SMAD2, *p=0.00276 and **p=0.011; SMAD3, *p=0.013,
**p=0.000168 and ***p=0.000888. f SMAD6, *p=0.0237 and **p=
0.00218
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a plasmid construct that overexpressed Smad6. This method
resulted in an increase in Smad6 mRNA and an associated
reduction in Col1a1 mRNAwithout affecting Smad3 expres-
sion (data not shown), supporting the involvement of Smad6
in regulating steady-state Col1a1 expression (Fig. 3b). Fur-
thermore, the addition of VPA resulted in a greater increase
in Smad6 transcripts, confirming the inductive effect of VPA
on Smad6 expression.
We performed a further experiment to investigate the effect
on Col1a1 expression when fibroblasts were simultaneously
transfected with shSmad3 and Smad6 overexpression vectors.
This method resulted in greater reduction in Col1a1 mRNA
expression compared to transfection with either plasmid alone
(Fig. 3c), corroborating the above data that both Smad3 and
Smad6 are involved in regulating Col1a1 expression. More-
over, greater Col1a1 transcript reductions were observed
when comparing plasmid transfections combined with VPA
treatment against either VPA treatment or plasmid transfec-
tions alone (Fig. 3c), reinforcing the notion that Col1a1 is
regulable by all three factors.
Fig. 3 Smad3 and Smad6 contribute to the inhibitory activity of VPA on
Col1a1 expression. a Real-time PCR analyses of Smad3 and Col1a1 in
conjunctival fibroblasts transfected with shSmad3 and/or treated with
VPA, as indicated. p values comparing fold changes in Smad3
expression between the indicated conditions are *p=0.000258, **p=
0.0359 and ***p=0.000130. p values comparing fold changes in
Col1a1 expression between the indicated conditions are *p=9.889e−8,
**p=3.497e−7 and ***p=0.00257. b Real-time PCR analyses of Smad6
and Col1a1 in conjunctival fibroblasts transfected with pSmad6 and/or
treated with VPA, as indicated. p values comparing fold changes in
Smad6 expression between the indicated conditions are **p=2.582e−8
and ***p=2.575e−. p values comparing fold changes in Col1a1
expression between the indicated conditions are *p=2.735e−6, **p=
2.372−-5 and ***p=0.0163. c Real-time PCR analyses of Smad3,
Smad6 and Col1a1 in conjunctival fibroblasts co-transfected with
shSmad3 and pSmad6 and/or treated with VPA, as indicated. p values
comparing fold changes in Smad3 expression between the indicated
conditions are *p=0.000887 and ***p=0.0218. p value comparing fold
changes in Smad6 expression between the indicated conditions is **p=
0.0218. p values comparing fold changes in Col1a1 expression between
the indicated conditions are *p=0.000193, **p=0.000820, ***p=
0.000226 and ****p=0.0418. a–c Data are presented as mean fold
change±SD. d Immunoblot analyses of SMAD2, SMAD3 and SMAD6
in fibroblasts cultured under the indicated conditions. Representative
immunoblots from one experiment are shown. Densitometry values,
normalised to GAPDH, represent the means±SD of the folds
expression of type I collagen relative to control cells co-transfected with
empty plasmid vectors
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We next performed immunoblotting experiments to verify
that the inhibition of type I collagen by Smad3 downregula-
tion, Smad6 overexpression and co-treatments with VPAwere
also reflected at the protein level (Fig. 3d). Indeed, exogenous
regulation of Smad3 and Smad6 expression levels modulated
type I collagen protein expression, with VPA being conspicu-
ously the most effective in doing so. Taken together, our data
indicate that basal Col1a1 reduction by VPA is mediated in
part by downregulating Smad3 and upregulating Smad6.
VPA suppresses type I collagen induced by TGF-β2
Since VPAmodulates Smad expression levels, it is reasonable
to predict that VPAwould disrupt TGF-β signaling. We there-
fore investigated the effect of VPA on the induction ofCol1a1
by TGF-β2. As expected, TGF-β2 alone significantly in-
duced type I collagen expression at both mRNA (Fig. 4a)
and protein levels (Fig. 4b). However, in the presence of
VPA, the influence of TGF-β2 on type I collagen expression
was subdued at both transcript (Fig. 4a) and protein levels
(Fig. 4b), indicating that the ability of TGF-β2 to induce col-
lagen above control levels is regulable by VPA.
It is possible that the failure of TGF-β2 to induce collagen
to above control levels may be due to either lower baseline
collagen levels caused by VPA and/or the inhibition of
TGF-β2 signaling by VPA. To address the second possibility,
we tested VPA in a reporter assay using the p3TP-Lux vector,
a widely used artificial promoter construct designed to dem-
onstrate maximal responsiveness to TGF-β [26] which can
also be activated by Smad3 and Smad4 overexpression [27].
Conjunctival fibroblasts were transfected with the p3TP-Lux
reporter plasmid followed by treatment with VPA and/or
TGF-β2 for 24 h.We observed that VPA significantly reduced
steady-state as well as TGF-β2-induced promoter activity of
the p3TP-Lux transcriptional reporter (Fig. 4c). Markedly,
type I collagen expression (Fig. 4b) and p3TP-Lux activity
(Fig. 4c) appeared to share a similar response profile under
the indicated conditions. Taken together, these data reveal that
VPA has the capacity to modulate the activity of the p3TP-
Lux promoter with or without TGF-β2, possibly contributed
in part by reduced Smad3 which we have shown to be
Fig. 4 VPA suppresses the induction of type I collagen by TGF-β2. a
Real-time PCR analyses of Col1a1 in fibroblasts stimulated as indicated
for 72 h. p value comparing fold changes in expression between TGF-β2-
treated and untreated control cells is *p=0.0113. p value comparing fold
changes in expression between co-treatment (TGF-β2 + VPA) and TGF-
β2 treatment is **p=0.00561. b Immunoblot analyses of type I collagen
in fibroblasts treated as indicated for 72 h. Representative immunoblots
from one experiment are shown. Densitometry values, normalised to
GAPDH, represent the means±SD of the folds expression of type I
collagen relative to untreated control. p values comparing fold changes
in type I collagen expression between the indicated conditions and
untreated control cells are *p=0.000950 and **p=0.00358. p value
comparing fold changes in expression between co-treatment (TGF-β2 +
VPA) and TGF-β2 treatment is ***p=0.0000846. c TGF-β2-responsive
promoter activity analysis. Fibroblasts were transfected with the p3TP-
lux reporter plasmid and treated as indicated for 24 h before firefly
luciferase activity was measured. Data were normalised to Renilla
luciferase activity from co-transfected pRL-TK and represented as mean
fold luciferase activity±SD relative to untreated cells. p values comparing
fold changes in luciferase activity between the indicated treatments and
untreated cells are *p=0.00559 and **p=0.00259. p value comparing
fold changes in luciferase activity between co-treatment (TGF-β2 +
VPA) and TGF-β2 treatment is ***p=0.000191. d Real-time PCR
analyses of Actb, Acta2 and Tnc in fibroblasts stimulated as indicated
for 72 h. p values comparing fold changes in expression between
treated and untreated control cells are Actb *p=0.00120, **p=
0.000654; Acta2 *p=0.0267, **p=0.000162, ***p=0.0153 and
****p=0.0173 (comparing between co-treatment (TGF-β2 + VPA) and
TGF-β2 treatment); Tnc *p=0.0202, **p=0.00519 and ***p=0.0334
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significantly reduced by 24 h (Fig. 2d). These observations
also confirm that collagen expression is sensitive to both
TGF-β2 and VPA activities.
Since TGF-β is known to induce myofibroblast transfor-
mation in fibroblasts, we also examined the impact of VPA on
this activity. In conjunctival fibroblasts, three markers for
myofibroblast differentiation, β-actin (Actb), α-smooth mus-
cle actin (Acta2) and tenascin C (Tnc), were induced by
TGF-β2 (Fig. 4d). Of these three genes, VPA modulated the
basal mRNA levels of Acta2 and Tnc2, but not Actb. Howev-
er, unlike Col1a1, the mRNAs of Acta2 and Tnc2 remained
above control levels when simultaneously treated with
TGF-β2 and VPA. We therefore assume that myofibroblast
differentiation induced by TGF-β2 may not be blocked by
VPA under the present experimental conditions. This finding
implies that the pathways regulating collagen induction and
the myofibroblast phenotype acquired by TGF-β2 stimulation
are multiple and overlapping and subject to differential sensi-
tivities to VPA regulation in conjunctival fibroblasts.
VPA abrogates the suppression of Smad6 by TGF-β2
We next determined whether VPA has the capacity to modu-
late TGF-β2 regulation of Smad expression. TGF-β2 alone
significantly suppressed the transcript expression of Smad2,
Smad3, Smad4 and Smad6 mRNAs in fibroblasts upon stim-
ulation for 72 h (Fig. 5a). The reduction of SMAD2 and
SMAD3 upon TGF-β2 stimulation was similarly observed
at the protein level, with SMAD3 being affected by a greater
extent compared to SMAD2 (Fig. 5b). Moreover, VPA did
not impede the capacity of TGF-β2 to phosphorylate
SMAD2 (Fig. 5b).
While co-treatment with TGF-β2 and VPA did not cause
further repression of Smad2, Smad3 and Smad4 transcripts
(Fig. 5a), the presence of VPA counteracted the inhibitory
effect of TGF-β2 on Smad6 at both the mRNA and protein
levels (Fig. 5a, c). To determine the involvement of Smad6 in
the TGF-β2-induction of type I collagen expression, we stim-
ulated the fibroblasts with TGF-β2 in combination with
Smad6 overexpression. Overexpression of Smad6 can signif-
icantly reduce the induction of Col1a1 transcripts by TGF-β2
(Fig. 5d). We further performed immunoblotting experiments
to verify that the modulatory relationship between TGF-β2,
Smad6 and VPA also occurs at the protein level. As can be
observed, the interplay between SMAD6 overexpression and
TGF-β2 stimulation resulted in variable induction of collagen
from the independent primary cultures (Fig. 5e). However, the
response of these cells to VPA was stable and highly repro-
ducible. Furthermore, SMAD6 overexpression further en-
hanced the inhibitory effect of VPA on the induction of type
I collagen by TGF-β2, confirming that SMAD6 is involved in
the regulation of type I collagen expression.
VPA inhibits type I collagen and upregulates Smad6
in the mouse model of GFS
To verify that VPA exerts similar effects on type I collagen
and Smad expression after experimental surgery on the con-
junctiva, we injected the drug into the conjunctiva in the
mouse model of GFS. We determined that VPA suppressed
Col1a1 transcript and protein expression in the late phase of
wound healing (day 7 post-surgery) but not in the early phase
(day 2 post-surgery) (Fig. 6a, b). Visualisation by polarised
microscopy of picrosirius red-stained bleb cryosections as
well as immunofluorescent analysis indicated a clear reduc-
tion in collagen fibres which was particularly conspicuous
near the episclera of the VPA-treated day-7 surgical site com-
pared to PBS control (Fig. 6c, arrowheads).
As with Col1a1, the injection of VPA did not cause signif-
icant differences in Smad expression in the early phase of
wound healing (day 2 post-surgery) (data not shown). How-
ever, in the late phase of wound healing, Smad6 mRNA and
protein levels were significantly and specifically upregulated
in response to VPA treatment (Fig. 6d, e). Hence, VPA is also
effective as a regulator of type I collagen in vivo and likely to
involve Smad6 mediation. Moreover, similarities between the
late-phase wound healing response, which likely involves
TGF-β2 [23], and the response of conjunctival fibroblasts to
VPA in the presence of TGF-β2 support the notion that these
cells are key responders to VPA and TGF-β2 in the late phase
of conjunctival wound healing.
Discussion
To our knowledge, the present study is the first to demonstrate
that VPA is an effective inhibitor of type I collagen expression
in conjunctival fibroblasts in the steady-state as well as in the
presence of the fibrogenic cytokine TGF-β2 via the selective
regulation of Smads. The mechanism for collagen regulation
in the steady-state by VPA involved the downregulation of
Smad2, Smad3 and Smad4 and the upregulation of Smad6.
On the other hand, VPA regulated TGF-β2-induced collagen
expression selectively via Smad6. The influence of VPA on
Col1a1 and Smad6 was reiterated in the experimentally oper-
ated conjunctiva during the late phase of wound healing when
TGF-β2 is likely to drive fibrotic development [23].
Our data is in agreement with previous studies which im-
plicated Smad3 in the regulation of steady-state type I colla-
gen expression. Overexpression of Smad3 stimulated basal
Col1a1 [28] and Col1a2 [29] promoter activities, independent
of TGF-β. Moreover, elevated Smad3 was observed in sclero-
derma fibroblasts which are characterised by the excessive
synthesis and accumulation of matrix proteins [30]. Converse-
ly, Smad3-deficient hepatic stellate cells expressed reduced
Col1a1 mRNA [5]. Similarly, we showed that suppression
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of Smad3 by either shRNA or VPAwas able to reduce steady-
state Col1a1 expression.
Smad3 may regulateCol1a1 expression by interaction with
DNA in association with other transcription factors. Smad3
complexed with Smad4 is essential for the former’s DNA
binding activity, independent of TGF-β [27, 31]. On the other
hand, Smad2 complexed with Smad4 was able to bind DNA
only in the presence of TGF-β [31], suggesting that it is un-
likely for downregulation of Smad2 by VPA to have a signif-
icant impact on steady-state Col1a1 expression. Incidentally,
Fig. 5 VPA modulates TGF-β2 effects on Col1a1 and Smad6
expression. a Real-time PCR analyses of Smad expression in fibroblasts
stimulated as indicated for 72 h. Data are presented as mean fold change±
SD relative to untreated cells. *p values comparing fold changes in
expression between TGF-β2-treated and untreated control cells are
shown where significant. p value comparing fold changes in expression
between co-treatment (TGF-β2 + VPA) and TGF-β2 treatment is **p=
0.0074. b Immunoblot analyses of phosphorylated SMAD2 (pSMAD2),
SMAD2 and SMAD3 in fibroblasts treated as indicated for 72 h.
Representative immunoblots from one experiment are shown.
Densitometry values, normalised to GAPDH, represent the means±SD
of the folds expression relative to untreated control. c Immunoblot
analyses of SMAD6 in fibroblasts treated as indicated for 72 h.
Representative immunoblots from one experiment are shown.
Densitometric analyses were performed as before. p value comparing
fold SMAD6 expression between the indicated conditions are *p=
0.0199 and **p=0.00849. d Real-time PCR analyses of Smad6 and
Col1a1 in conjunctival fibroblasts transfected with pSmad6 and/or
treated with VPA in the presence of TGF-β2. Data are presented as
mean fold change±SD relative to cells transfected with control plasmid,
as represented by the dotted line. p values comparing fold changes in
Smad6 expression between the indicated conditions are *p=0.0461 and
**p=0.000511. p values comparing fold changes in Col1a1 expression
between the indicated conditions are *p=0.0232 and ***p=0.0135. e
Immunoblot analyses of SMAD6 and type I collagen in fibroblasts
subjected to the indicated conditions. Representative immunoblots from
one experiment are shown. Densitometry values represent the mean fold
expression±SD of type I collagen relative to cells transfected with control
plasmid, as represented by the dotted line. p value comparing fold
changes in type I collagen expression between co-treatment (TGF-β2 +
VPA) and co-treatment cum SMAD6 overexpression is *p=0.0043
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Smad4 was demonstrated to be necessary for basal type I
collagen expression in kidney mesangial cells [32]. Hence,
reduced Smad3 coupled with decreased expression of its
partner Smad4 by VPA is likely to strengthen the suppression
of Col1a1 basal promoter activity ensuring reduced steady-
state type I collagen expression. Moreover, Smad3 has been
Fig. 6 VPA suppresses type I collagen and upregulates Smad6 in the late
phase of conjunctival wound healing. a Real-time PCR analyses of
Col1a1 expression in the day 2 and day 7 post-operative tissues. Each
symbol represents a pool of 5 operated left eyes and is calculated as fold
change over the corresponding pool of 5 contralateral un-operated right
eyes. Horizontal bars represent the mean fold change for each
experimental arm. The mean fold change and p value comparing VPA
treatment relative to PBS control on day 7 are shown. b Immunoblot
analyses of type I collagen expression in the day 7 operated
conjunctival tissues. Representative immunoblots from one experiment
are shown. Densitometry values, normalised to GAPDH, represent the
means±SD of the folds expression of type I collagen in VPA relative to
PBS treated tissues from 3 independent experiments, each consisting of
pooled tissues from 5 eyes of each treatment condition. The mean fold
change and p value comparing the two conditions are shown. C,
contralateral un-operated conjunctival tissues. c Histochemical and
immunofluorescence analyses of collagen deposition in cryosections of
the day 7 operated tissues. Left panels, cryosections stained with
picrosirius red and visualised by polarised microscopy. Scale bar,
200 μm. Right panels, cryosections immunostained with anti-type I
collagen antibodies (red). Nuclei were visualised by DAPI staining
(blue). Arrows indicate sutures. Scale bar, 50 μm. CE, conjunctival
epithelium; S, sclera. d Real-time PCR analyses of Smad genes in the
day 7 operated conjunctival tissues. The meaning of each symbol is as
described in (a). e Immunoblot analyses of SMAD6 in the day 7 operated
conjunctival tissues. Representative immunoblots from one experiment
are shown. Densitometric analysis, shown below the representative blot,
was performed as stated in (b)
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detected in a complex with AP-1, a key transcription factor in
profibrogenic signaling [33]. Increased binding of the AP-1
complex to DNA via Smad3/Smad4 co-overexpression was
shown to be sufficient for transcriptional activation [27]. Most
importantly, this complex is likely to be important for collagen
regulation since VPA disrupted the binding of the AP-1 com-
plex to DNA in pancreatic stellate cells, resulting in reduced
collagen synthesis [34]. Our data and observations made by
others therefore suggest that VPA may reduce steady-state
collagen expression on two fronts: by reducing Smad3/
Smad4 levels as well as disrupting the interaction of the
Smad3/Smad4/AP-1 complex with DNA.
Reduction of steady-state type I collagen expression by
VPA is also likely to be exacerbated by increase in inhibitory
Smad6 expression by VPA. Smad6 was reported to be asso-
ciated with HDAC [35] which may have a role in promoting
protein degradation, as has been shown for Smad7. Smad7 is
known to be acetylated by p300/CBP which protects it from
ubiquitination and TGF-β-induced degradation [36]. Smad7
interaction with HDACs promoted its degradation by
deacetylation [37]. We therefore speculate that Smad6 may
be similarly regulated and VPA may enhance Smad6 stability
via HDAC inhibition.
The steady-state cellular localization of SMAD6 to both
the nucleus and the cytosol [38, 39] suggests that Smad6 has
the capacity to regulate basal Smad-mediated transcription
activity. Smad6 was suggested to function as a transcription
repressor or co-repressor by tightening the chromosome struc-
ture via complex formation with HDAC and binding to DNA
[35]. Since VPA treatment was able to intensify Col1a1 inhi-
bition by Smad6 overexpression, the role of HDAC-
associated chromatin-remodeling in Col1a1 gene transcrip-
tion regulation is likely not a predominant one. The issue of
whether Smad6 regulates steady-state Col1a1 expression by
competing with Smad4 to form an inactive complex with R-
Smads [40] remains to be investigated.
We have elected to investigate the interaction of VPAwith
TGF-β2 activities in conjunctival fibroblast collagen expres-
sion since this is the major isoform of the TGF-β family in-
volved in subconjunctival fibrosis [41, 42]. Moreover, we
have previously shown that TGF-β2 was induced in the late
phase of wound healing in a mouse model of GFS and there-
fore likely to be a key source of the fibrogenic signal in vivo
[23]. The relevance for modulating HDAC activity in the
presence of TGF-β is underscored by the demonstration that
TGF-β1 induced a general increase in HDAC activity in hu-
man osteoblasts and treatment with VPA was able to alter
TGF-β1 signaling in these cells [43].
Numerous studies have implicated Smad3 as the key me-
diator of the fibrogenesis signaling pathway incited by TGF-β
signals [4, 44]. However, our study revealed that modulation
of TGF-β2 induction of collagen by VPA selectively involved
Smad6. Parallels may be drawn between the impact of VPA
and TGF-β2 on Smad6 expression and the capacity of
trichostatin A, also an HDAC inhibitor, to rescue TGF-β1-
suppressed Smad7 in nasal polyp-derived fibroblasts [45].
Our finding is unanticipated because Smad6 is best known
as a specific inhibitor of BMP signaling [46] whereas Smad7
is commonly associated with TGF-β/activin signaling [47].
However, recent evidence indicated that Smad6, but not
Smad7, interfered with non-canonical TGF-β signaling by
negatively regulating the TRAF6-TAK1-p38 MAPK/JNK
pathway [48]. Given that signaling pathways mediated by
ERK1/2 MAPK, p38 MAPK and PI3K/Akt/PKB are known
to be important in regulating collagen expression [1], collagen
induction by TGF-β2 essentially involves both Smads and
Smad-independent non-canonical TGF-β pathways. Indeed,
the additive nature of Smad signaling and non-canonical path-
ways such as p38 MAPK signaling in TGF-β regulation of
collagen expression has been reported [49]. Our study now
brings to light the potential involvement of Smad6 in nega-
tively regulating Smad-independent non-canonical TGF-β
pathways that lead to collagen induction and fibrogenesis. It
is therefore conceivable that targeting Smad6 will be benefi-
cial as part of an anti-fibrogenic therapeutic strategy.
The differential effects of VPA on the induction of
myofibroblast markers and collagen by TGF-β2, suggest that
multiple pathways, with potential overlaps, may be involved
in delivering these two end-points. Indeed, myofibroblast dif-
ferentiation induced by TGF-β involves not only Smads [50]
but other pathways such as integrin signaling [51]. The in-
volvement of multiple overlapping pathways may explain
why TGF-β2-induced Col1a1 was effectively suppressed by
VPA but not similarly induced Acta2 and Tnc, although all
three were highly regulable by VPA per sé. These observa-
tions serve to highlight the consistent effectiveness of VPA on
collagen inhibition, be it in the steady-state or upon fibrogenic
activation by TGF-β2.
Collectively, our data clearly implicated VPA as an effec-
tive therapeutic for reducing collagen accumulation in con-
junctival fibrosis via a mechanism that involves Smads. On
the other hand, our findings also allude to collagen deficiency
as a potential side effect of systemic long-term use of VPA
since it has the capacity to regulate steady-state collagen ex-
pression. Indeed, bone loss as a long-term side effect of VPA
medication has been described [52]. Furthermore, a proteome
study of a spinal muscular atrophy cell line treated with VPA
revealed that out of more than one thousand proteins evaluat-
ed, collagens I and VI were strikingly reduced in these cells
[53]. Hence, it is helpful that a eukaryotic receptor for VPA,
which is homologous to themammalian solute carrier family 4
(SLC4] bicarbonate transporter, has recently been identified
[54]. Further in-depth evaluation of VPA cellular effects and
mechanisms, coupled with regulated drug uptake, may help
towards optimising the clinical benefits of VPA while
minimising possible side effects.
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